Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The inflamed liver in chronic hepatitis B virus (HBV) infection (CHB) is characterized by a large influx of non–virus-specific CD8 T cells. Little is known about the functional capacity of these lymphocytes, which could provide insights into mechanisms of failure of viral control and liver damage in this setting. We compared the effector function of total circulating and intrahepatic CD8 T cells in CHB patients and healthy donors. We demonstrated that CD8 T cells from CHB patients, regardless of their antigen specificity, were impaired in their ability to produce interleukin-2 and proliferate upon TCR-dependent stimulation. In contrast, these CD8 T cells had preserved production of the proinflammatory cytokines interferon-γ and tumor necrosis factor-α. This aberrant functional profile was partially attributable to down-regulation of the proximal T cell receptor signaling molecule CD3ζ, and could be corrected in vitro by transfection of CD3ζ or replenishment of the amino acid arginine required for its expression. We provide evidence for depletion of arginine in the inflamed hepatic microenvironment as a potential mechanism for these defects in global CD8 T cell signaling and function. These data imply that polarized CD8 T cells within the HBV-infected liver may impede proliferative antiviral effector function, while contributing to the proinflammatory cytokine environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. CD3ζ is down-regulated in both peripheral and intrahepatic CD8 from patients with chronic HBV. PBMCs or intrahepatic lymphocytes isolated from biopsy tissue were surface stained for CD3ε and CD8, fixed, permeabilized, and stained for intracellular CD3ζ or its isotype. A tight lymphocyte gate and secondary gate over CD3ε+CD8 cells has been applied. A marker was applied at the edge of the isotype control (solid black line) and the proportion of CD8 to the right of this line represented the CD3ζ+ fraction. (a) Representative flow cytometric histogram illustrating CD3ζ expression (as a percentage and as mean fluorescence intensity [MFI]) for a chronic HBV-infected patient with high viral load (>106 IU/ml; dashed line) and a healthy control (gray). (b) CD3ζ levels, shown as both MFI and percentage of CD3ζ+ in the total CD8 are shown against viral load (top), and percentage values are further broken down by HBeAg status and ALT (bottom). (c) Histogram to illustrate differential expression of CD3ζ by peripheral (dark gray) and intrahepatic (light gray) CD8 from a CHB donor (dotted line, isotype). (d) The difference in CD3ζ expression between intrahepatic and peripheral CD8 is plotted for each patient with HBV/non-HBV–related liver disease.](https://figures.cochat.ai/paper-figures/7ff43f33481548d4a97e76a0dcd07fd0/functional-skewing-of-the-global-cd8-t-cell-population-in-chronic-hepatitis-b-figure-4.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effector and memory T-cell differentiation: implications for vaccine development
Kaech, S. M., Wherry, E. J., & Ahmed, R. (2002) · Nature Reviews Immunology · doi:10.1038/nri778 · Cited by 1,865
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R., & Ahmed, R. (2003) · Journal of Virology · doi:10.1128/jvi.77.8.4911-4927.2003 · Cited by 1,610
Phenotypic and functional separation of memory and effector human CD8+ T cells
Hamann, D., Baars, P. A., Rep, M. H. G., Hooibrink, B., Kerkhof-Garde, S. R., Klein, M. R., & Lier, R. A. W. V. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.9.1407 · Cited by 1,366
Frumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Intracellular Inactivation of the Hepatitis B Virus by Cytotoxic T Lymphocytes
Guidotti, L. G., Ishikawa, T., Hobbs, M. V., Matzke, B., Schreiber, R., & Chisari, F. V. (1996) · Immunity · doi:10.1016/s1074-7613(00)80295-2 · Cited by 1,083
Fallarino, F., Grohmann, U., You, S., McGrath, B. C., Cavener, D. R., Vacca, C., Orabona, C., Bianchi, R., Belladonna, M. L., Volpi, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.11.6752 · Cited by 1,047
Thimme, R., Wieland, S., Steiger, C., Ghrayeb, J., Reimann, K. A., Purcell, R. H., & Chisari, F. V. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.68-76.2003 · Cited by 979
L-arginine availability regulates T-lymphocyte cell-cycle progression.
Rodriguez, P. C., Quiceno, D. G., & Ochoa, A. C. (2007) · Blood · doi:10.1182/blood-2006-06-031856 · Cited by 926
Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection
Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Laccabue, D., Zerbini, A., Cavalli, A., Missale, G., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02844-06 · Cited by 920
Self-citation
Research works printed but not linked: 3
- 1993, Cancer Res., 53, 5610
- 1991, Transplant. Proc., 23, 1436
- 1995, Hepatology., 21, 1585
Cited by
Items 101–200 of 263
Liu, H., Li, F., Zhang, X., Yu, J., Wang, J., Jia, J., Yu, X., Shen, Z., Yuan, Z., Zhang, X., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix683 · Cited by 44
Design of therapeutic vaccines: hepatitis B as an example
Kutscher, S., Bauer, T., Dembek, C. J., Sprinzl, M. F., & Protzer, U. (2011) · Microbial Biotechnology · doi:10.1111/j.1751-7915.2011.00303.x · Cited by 43
Kosinska, A. D., Johrden, L., Zhang, E., Fiedler, M., Mayer, A., Wildner, O., Lu, M., & Roggendorf, M. (2012) · Journal of Virology · doi:10.1128/jvi.00506-12 · Cited by 41
“Since the introduction of prophylactic vaccination programsagainst hepatitis B in over 170 countries, the number of new infections with hepatitis B virus (HBV) has been continuously decreasing.”
BackgroundInfluentialFibrosis in chronic viral hepatitis
Calvaruso, V., & Craxì, A. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.012 · Cited by 40
Wu, X., Zhang, J., Huang, A., Li, Y., Zhang, S., Wei, J., Xia, S., Wan, Y., Chen, W., Zhang, Z., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit312 · Cited by 40
“filtrated non–virus-specific leukocytes as well as skewed cytokine and chemokine profiles [3–5].”
BackgroundTherapeutic vaccination and novel strategies to treat chronic HBV infection
Bertoletti, A., & Gehring, A. J. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.48 · Cited by 39
Self-citationTrehanpati, N., Kotillil, S., Hissar, S. S., Shrivastava, S., Khanam, A., Baweja, S., Mishra, S. K., & Sarin, S. K. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9509-7 · Cited by 39
Dandri, M., Bertoletti, A., & Lütgehetmann, M. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00864-x · Cited by 38
Self-citationMedikonda, R. T., Abikenari, M. A., Schonfeld, E., & Lim, M. K. (2025) · Cancers · doi:10.3390/cancers17111881 · Cited by 37
“Arginine is required for synthesis of the T cell receptor (TCR), and its depletion in the TME results in decreased TCR expression [79] as well as reduced cytokine secretion and T cell proliferation [80].”
Wu, D., & Ning, Q. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix355 · Cited by 37
Yang, S., Zeng, W., Zhang, J., Lu, F., Chang, J., & Guo, J. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1952851 · Cited by 40
HBV-Specific Adaptive Immunity
Bertoletti, A., Tan, A. T., & Gehring, A. J. (2009) · Viruses · doi:10.3390/v1020091 · Cited by 34
“has shown that depletion of arginine in the inflamed liver can directly interfere with intrahepatic T cell function, particularly with their ability to produce IL-2 and proliferate [71].”
BackgroundSelf-citationWalker, L. J., Marrinan, E., Muenchhoff, M., Ferguson, J. G., Kløverpris, H. N., Cheroutre, H., Barnes, E. J., Goulder, P., & Klenerman, P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00223 · Cited by 34
“A similar observation of a large CD28−CD8 T cell population has also been made in chronic hepatitis B (HBV) associated with higher viral load and liver inflammation (34).”
BackgroundMurthy, A., Shao, Y. W., Defamie, V., Wedeles, C. J., Smookler, D. S., & Khokha, R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102199 · Cited by 35
“, hepatitis B virus, hepatitis C virus, and CMV models of viral infection; Listeria monocytogenes and Mycobacterium tuberculosis models of bacterial infection) will prove useful in delineating the contribution of Timp genes to acute CD8 CTL or CD4 T cell responses against virus (32, 33), and T helper subset function a…”
BackgroundWen-jin, Z., Chuanhui, P., Yunle, W., Lateef, S. A., & Shusen, Z. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-109 · Cited by 32
CTLA‑4 interferes with the HBV‑specific T�cell immune response (Review)
Cao, H., Zhang, R., & Zhang, W. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3688 · Cited by 32
“By contrast, functional skewing of the global CD8+ T cell population led to impairment in their ability to produce cytokines [interleukin (IL)‐2, interferon (IFN)‐γ and tumor necrosis factor (TNF) α] and to proliferate in cells with chronic hepatitis B virus (CHB) infection (24).”
Ouaguia, L., Mrizak, D., Renaud, S., Moralès, O., & Delhem, N. (2014) · Mediators of Inflammation · doi:10.1155/2014/564296 · Cited by 36
“Another mechanism in inflammation control is the constitutive expression of arginase by hepatic cells, an enzyme which inhibits the lymphocytes proliferation [74].”
BackgroundСтарикова, Э. А., Rubinstein, A., Mammedova, J. T., Isakov, D., & Kudryavtsev, I. V. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040231 · Cited by 30
Han, Q., Li, N., Zhu, Q., Zhu, L., Zhang, G., Chen, J., Lv, Y., Wang, Y., Liu, Z., & Hao, C.-Q. (2012) · Clinical and Experimental Medicine · doi:10.1007/s10238-012-0214-5 · Cited by 31
“The phases of chronic HBV infection are characterized by different levels of immunoregulatory and inflammatory responses of the hosts to various degrees of the HBV viral replication, in which natural killer (NK) cells [12–14], CD4? and CD8? T-lymphocytes [15, 16], dendritic cells [17] and regulatory T cells [18, 19] a…”
BackgroundShrivastava, S., Trehanpati, N., Patra, S., Kottilil, S., Pande, C., Trivedi, S. S., & Sarin, S. K. (2013) · Journal of Viral Hepatitis · doi:10.1111/jvh.12078 · Cited by 30
Deng, Q., Bourgine, M., Zhang, X., Cumont, M., Zhu, R., Lone, Y. C., & Michel, M. (2009) · Hepatology · doi:10.1002/hep.23150 · Cited by 30
Human Neutrophil Peptide 1 as immunotherapeutic agent against Leishmania infected BALB/c mice
Abdossamadi, Z., Seyed, N., Zahedifard, F., Taheri, T., Taslimi, Y., Montakhab‐Yeganeh, H., Badirzadeh, A., Vasei, M., Gharibzadeh, S., & Rafati, S. (2017) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0006123 · Cited by 31
“In various infectious, diseases such as leishmaniasis, trypanosomiasis and viral infection, are concordance with IL-4 as well as IL-10 production (as Th2 cytokines) and L-Arg increased catabolism in M2 macrophages [57,58].”
BackgroundAllahmoradi, E., Mohammadi, R., Zarandi, P. K., Alavian, S. M., & Heiat, M. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2198209 · Cited by 32
“In this context, two studies were investigated the role of CD4+ T cells and the results showed that defect in CD4+ help such as production of IL-2 and IL-21, impaired CD8+ T cells division [114,115].”
BackgroundChang, K., Traum, D., Park, J., Ho, S., Ojiro, K., Wong, D., Wahed, A. S., Terrault, N. A., Khalili, M., Sterling, R. K., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007715 · Cited by 29
Fierro, N. A., Román, S., Realpe, M., Nazará, Z., Zepeda-Carrillo, E. A., & Panduro, A. (2011) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762011000800018 · Cited by 29
“A decreased ability to produce IL-2 in HBV-infected patients with higher viral loads (Das et al. 2008) and the fact that high concentrations of IL-2 in the serum are related with an early and spontaneous seroconversion and disease resolution (Debnath et al.”
BackgroundShi, Y., Wu, W., Wan, T., Liu, Y., Peng, G., Chen, Z. J., & Zhu, H. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.10.023 · Cited by 28
“In several clinical settings, such as malignancy [30], chronic viral (HBV [31], HIV [32]) and bacterial infections [33], T cells were reported to be impaired in their ability to proliferate and produce effector cytokines upon TCR-associated stimulation.”
BackgroundHepatitis B virus: from immunobiology to immunotherapy
Grimm, D. G., Heeg, M., & Thimme, R. (2012) · Clinical Science · doi:10.1042/cs20120169 · Cited by 30
Cai, G., Nie, X., Li, L., Hu, L., Wu, B., Lin, J., Jiang, C., Wang, H., Wang, X., & Shen, Q. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0762-9 · Cited by 27
“munoresponse was observed during chronic infection, in which T lymphocytes are dysfunctional [2, 3].”
BackgroundT-cell therapy for chronic viral hepatitis
Bertoletti, A., Tan, A. T., & Koh, S. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.07.011 · Cited by 28
Self-citationLi, N., Zhu, Q., Zhu, L., Han, Q., Chen, J., Lv, Y., Wang, Y., Zeng, X., Chen, Y., Yang, C., et al. (2013) · Human Immunology · doi:10.1016/j.humimm.2013.01.005 · Cited by 27
Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology
Bengsch, B., & Chang, K. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.06.001 · Cited by 27
Combination Therapy for Chronic Hepatitis B: Current Updates and Perspectives
Su, T., & Liu, C. (2017) · Gut and Liver · doi:10.5009/gnl16215 · Cited by 30
“, HBeAg and HBsAg) have been linked to T-cell exhaustion in patients with CHB.(10,11) PegIFN-α and NUCs have differential effects on the innate and adaptive immune responses.”
BackgroundInfluentialGehring, A. J. (2017) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2017.05.004 · Cited by 28
Taking off the brakes: T cell immunity in the liver
Kern, M., Popov, A., Kurts, C., Schultze, J. L., & Knolle, P. A. (2010) · Trends in Immunology · doi:10.1016/j.it.2010.06.001 · Cited by 30
Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly
Costa, H. E., Gouilly, J., Abravanel, F., Bahraoui, E., Péron, J., Kamar, N., Jabrane‐Ferrat, N., & Izopet, J. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009367 · Cited by 26
“Pro-inflammatory cytokine microenvironment during acute infection, depletion/accumulation of some metabolites and/or innate-like functions of CD8 T cells can also trigger the activation of EM cells in the absence of cognate antigens as well as their functional skewing [23,26,30,33,36].”
BackgroundHighly activated TRAIL+ CD56bright NK cells are associated with the liver damage in HBV-LC patients
Jiang, Y., Qin, S., Wei, X., Liu, X., Guan, J., Zhu, H., Chang, G., Chen, Y., Lu, H., Qian, J., et al. (2021) · Immunology Letters · doi:10.1016/j.imlet.2020.12.008 · Cited by 25
Regulation of T cell function by microRNA-720
Wang, Y., Zhang, Z., Ji, D., Chen, G.-F., Feng, X., Gong, L., Guo, J., Li, Z., Chen, C., Zhao, B.-B., et al. (2015) · Scientific Reports · doi:10.1038/srep12159 · Cited by 26
Bayard, F., Godon, O., Nalpas, B., Costentin, C. E., Zhu, R., Soussan, P., Vallet‐Pichard, A., Fontaine, H., Mallet, V. O., Pol, S., et al. (2012) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2012.01611.x · Cited by 25
Immune response pattern varies with the natural history of chronic hepatitis B
Wang, W., Zhao, X.-Q., Li, G., Chen, Y., Wang, L., Han, M., Li, W., Chen, T., Chen, G., Xu, D., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i16.1950 · Cited by 30
Middlebrook, E. A., Romero, A. T., Bett, B., Nthiwa, D., Oyola, S. O., Fair, J. M., & Bartlow, A. W. (2022) · Zoonoses and Public Health · doi:10.1111/zph.12905 · Cited by 24
Nitric oxide and l -arginine metabolism in a devascularized porcine model of acute liver failure
Sharma, V., Have, G. A. M. T., Ytrebø, L. M., Sen, S., Rose, C. F., Dalton, R. N., Turner, C., Revhaug, A., van Eijk, H. M. H., Deutz, N. E. P., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00268.2011 · Cited by 24
“Similarly, an increase in the level of plasma arginase, released during hepatic stresses (8), can reduce the amount of available arginine, preventing eNOS-mediated NO synthesis.”
BackgroundMethodSelf-citationREVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics
Chang, K., & Liu, M. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.013 · Cited by 23
“arginine) through arginase released by MDSC and damaged hepatocytes [67,93].”
BackgroundMethodIntrahepatic NK cells function suppressed in advanced liver fibrosis
Li, X., Zhang, M., Liu, J., Huang, Z., Zhao, Q., Huang, Y., Li, X., & Gao, Z. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12669 · Cited by 27
Identification of FDA‐approved drugs that target hepatitis B virus transcription
van de Klundert, M. A. A., Zaaijer, H. L., & Kootstra, N. A. (2015) · Journal of Viral Hepatitis · doi:10.1111/jvh.12479 · Cited by 22
Zhao, B.-B., Zheng, S.-J., Gong, L., Wang, Y., Chen, C., Jin, W.-J., Zhang, D., Yuan, X., Guo, J., Duan, Z., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077008 · Cited by 22
“global CD8+ T-cells [13,15,26–28].”
Yang, J., Chen, J., He, J., Xie, Y., Zhu, Y., Cao, H., & Li, L. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.22 · Cited by 21
Abdossamadi, Z., Taheri, T., Seyed, N., Montakhab‐Yeganeh, H., Zahedifard, F., Taslimi, Y., Habibzadeh, S., Gholami, E., Gharibzadeh, S., & Rafati, S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0076 · Cited by 25
The immune response in chronic HBV infection
Bertoletti, A. (2024) · Journal of Viral Hepatitis · doi:10.1111/jvh.13962 · Cited by 22
“…releases amino-acid degrading enzymes like arginase and tryptophan-2,3 dioxygenase that reduce the intrahepatic availability of argi-nine—an essential amino acid for T cell function 135,136 or increases the presence of tryptophan-derived catabolites that curtail CD8 T cell function 137 (Figure 2D).”
Self-citationDou, Y., van Montfoort, N., van den Bosch, A., de Man, R. A., Zom, G. G., Krebber, W.-J., Melief, C. J. M., Buschow, S. I., & Woltman, A. M. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix614 · Cited by 21
Argemí, J., Ponz‐Sarvisé, M., & Sangro, B. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.03.002 · Cited by 22
Jansen, D. T. S. L., Dou, Y., de Wilde, J. W., Woltman, A. M., & Buschow, S. I. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1232 · Cited by 21
“T-cell responses to HBV antigens boosted/induced by TV may be further improved by ICB, costimulatory agonists and drugs altering T-cell metabolism.(10,24,32,114,115) As outlined above, recent studies strongly indicate that for each viral protein the mechanisms and deficits of T-cell priming are different and likewise…”
BackgroundKoh, S., & Bertoletti, A. (2014) · Medical Microbiology and Immunology · doi:10.1007/s00430-014-0377-7 · Cited by 18
“These cytokines or liver enzymes are known to alter the function of different components of cellular immunity [37, 38].”
BackgroundSelf-citationFocus on T cell exhaustion: new advances in traditional Chinese medicine in infection and cancer
Li, S., Hao, L., Zhang, J., Deng, J., & Hu, X. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00785-x · Cited by 17
“HBV Anti-CD3, and anti-CD28 Arginine [82]”
BackgroundInfluentialKutscher, S., Allgayer, S., Dembek, C. J., Bogner, J. R., Protzer, U., Goebel, F. D., Erfle, V., & Cosma, A. (2010) · Gene Therapy · doi:10.1038/gt.2010.90 · Cited by 17
Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B
Zhang, W., Peng, C.-H., & Zheng, S. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60061-2 · Cited by 16
Han, M., Li, Y., Wu, W., Zhang, Y., Yan, W., Luo, X., & Ning, Q. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.10.003 · Cited by 15
Santiago-Olivares, C., Rivera-Toledo, E., & Gómez, B. (2019) · Archives of Virology · doi:10.1007/s00705-019-04259-0 · Cited by 15
Démolis, L. L., Henriquez, S., Lambotte, O., Santo, J. P. D., Grand, R. L., Pflumio, F., Arcangeli, M.-L., Legrand, N., & Bourgeois, C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5hi1018-410rr · Cited by 15
Yang, J., He, J., Lu, H., Wei, L., Li, S., Wang, B., Diao, H., & Li, L. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-210 · Cited by 15
“This is consistent with previous reports demonstrating that proliferating HBVantigen specific T cells were CD8 T cells rather than CD4 [23].”
ResultInfluentialYang, J., Chen, J., Mao, H., Yi, P., Yan, D., He, J., & Li, L. (2012) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2012.00969.x · Cited by 14
Stimulatory Toll-like receptor 2 suppresses restraint stress-induced immune suppression
Hu, D., Denney, J., Liang, M., Javer, A., Yang, X., RuiLiang, Z., & Yin, D. (2013) · Cellular Immunology · doi:10.1016/j.cellimm.2013.05.007 · Cited by 14
“However, except for CD4+ T cells, CD8+ T cells can produce IL-2 and IL-4 cytokines upon activation by T cell stimulator [28, 29].”
BackgroundLenalidomide acts as an adjuvant for HCV DNA vaccine
Borhani, K., Bamdad, T., & Hashempour, T. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.05.007 · Cited by 13
Xiong, Y., Tan, Y. Q., & Song, Y. G. (2014) · Hepatitis Monthly · doi:10.5812/hepatmon.15900 · Cited by 12
Rexhouse, C., Bailey, J. T., Moshkani, S., Cimino, J. L., & Robek, M. D. (2025) · Journal of Virology · doi:10.1128/jvi.00711-25 · Cited by 12
“During chronic infection, HBV-specific T cells are low in number and become functionally impaired, losing cytokine production and proliferative ability while upregulating inhibitory receptors (7, 8).”
Khanam, A., Ghosh, A., Chua, J. V., & Kottilil, S. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04104-8 · Cited by 11
“(1) T cell proliferation: T cell proliferation is a critical step for the clonal expansion of antigen-specific T cells and their further transition into effector cells, which is a fundamental requirement to mount an effective T cell response [30].”
BackgroundRegulatory natural killer cells in murine liver and their immunosuppressive capacity
Yoshida, O., Akbar, S. M. F., Chen, S., Miyake, T., Abe, M., Murakami, H., Hiasa, Y., & Onji, M. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02253.x · Cited by 11
Laupèze, B., Vassilev, V. B., & Badur, S. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2268503 · Cited by 10
“Chimeric antigen receptor T cell therapies, which are increasingly being used for the treatment of hematological malignancies, have been proposed, but this method is complex and unlikely to be adopted widely as a routine treatment for CHB using current technology [89].”
BackgroundLi, J., Li, J., Bao, Y., Pan, K., Lin, X., Liu, X., Wang, H., Xu, Y. X., Luo, X., Li, H., et al. (2015) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.21838 · Cited by 10
Classifying hepatitis B therapies with insights from covalently closed circular DNA dynamics
Hu, J., & Huang, A. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.12.005 · Cited by 11
“Inhibiting cIAPs, therefore, leads to increased TNF-mediated cell death.”
BackgroundModulation of Antigen-Specific T-Cells as Immune Therapy for Chronic Infectious Diseases and Cancer
Li, S., Symonds, A. L. J., Miao, T., Sanderson, I. R., & Wang, P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00293 · Cited by 12
“Down-regulation of TCR proximal signaling molecules has been found in CD8 T cells from chronic HBV patients (25).”
BackgroundInfluentialLiu, M., Miao, T., Zhu, H., Symonds, A. L. J., Li, L., Schurich, A., Maini, M. K., Zhang, J., Kennedy, P. T. F., Li, S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102709 · Cited by 10
“Evidence of T cell exhaustion has been found in both virus-specific and nonspecific CD8 T cells in chronic HBV patients (3, 10).”
BackgroundInfluentialSelf-citationWong, D. J., LOCARNINI, S. A., & Thompson, A. J. V. (2016) · ASM Press eBooks · doi:10.1128/9781555819439.ch32 · Cited by 9
HIV/HBV coinfection remodels the immune landscape and natural killer cell ADCC functional responses
Sun, B., da Costa, K., Alrubayyi, A., Kokiçi, J., Fisher-Pearson, N., Hussain, N., D’Anna, S., Piermatteo, L., Salpini, R., Svicher, V., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000877 · Cited by 10
“[44] A more in-depth assessment is required to evaluate the factors involved that can be manipulated to enhance NK cell activity, especially in HBV mono-infection.”
Self-citationClinical Trial Design for Immune-Based Therapy of Hepatitis B Virus
Gill, U. S., & Bertoletti, A. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1600522 · Cited by 9
Self-citationCD8+CD28− T cells: key cytotoxic players impacting disease pathogenesis in chronic HBV infection
Nandi, M., Pal, S., Ghosh, S., Chakraborty, B. C., Dey, D., Baidya, A., Shil, A., Chattopadhyaya, S., Banerjee, S., Santra, A. K., et al. (2019) · Clinical Science · doi:10.1042/cs20190369 · Cited by 9
Yang, J., Lu, H., Guo, R., Dong, Y., Ye, P., Jin, L., Chen, C., Cao, H., Diao, H., & Li, L. (2014) · Pathogens and Disease · doi:10.1093/femspd/ftu018 · Cited by 9
Darmadi, D., Lindarto, D., Siregar, J., Widyawati, T., Rusda, M., Amin, M. M., Yusuf, F., Eyanoer, P. C., Lubis, M., & Rey, I. (2023) · Medical Archives · doi:10.5455/medarh.2023.77.227-230 · Cited by 8
“T-cell activation is influenced by Cytotoxic T Lymphocyte Antigen-4 (CTLA-4), which is a signaling molecule inhibiting T-cell responses (8, 9).”
BackgroundZhang, P., Li, N., Zhu, Q., Li, F., Yang, C., Zeng, X., Lv, Y., Zhou, Z.-H., Han, Q., & Liu, Z. (2015) · Virology Journal · doi:10.1186/s12985-015-0268-6 · Cited by 8
“The intensity of immuno-inflammatory responses of the hosts to various levels of the HBV viral replication characterizes the natural course of chronic HBV infection and has been extensively studied, showing that immunoinflammatory responses associated with various types of cells are involved in the course [4-9].”
BackgroundBlock, P. D., Shinn, B., Kim, J. H., & HANN, H.-W. L. (2020) · Hepatic Oncology · doi:10.2217/hep-2020-0028 · Cited by 9
What Is the Current Status of Hepatitis B Virus Viro-Immunology?
Boni, C., Rossi, M., Montali, I., Tiezzi, C., Vecchi, A. L., Penna, A., Doselli, S., Reverberi, V., Berti, C. C., Montali, A., et al. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.05.001 · Cited by 8
Decoding HBV-specific adaptive immunity: from natural clearance to cure
Thimme, R., Hofmann, M., Bertoletti, A., & Bert, N. L. (2025) · Gut · doi:10.1136/gutjnl-2025-337129 · Cited by 11
“63 Indeed, it has been shown that myeloid suppressor cells enriched in the HBV-inflamed liver produce the enzyme arginase-1, which catabolises arginine, an amino acid essential for T cell proliferation.”
Self-citationKondo, Y., Ueno, Y., & Shimosegawa, T. (2009) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-009-0074-z · Cited by 7
Czarnecka, A. M., Aleksandrowicz, M., Jasiński, K., Jaźwiec, R., Kalita, K., Hilgier, W., & Zielińska, M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14578 · Cited by 7
“Furthermore, an increased level of plasma arginase during liver failure (Das et al. 2008) can additionally lower the supply of available arginine, reducing NO synthesis via endothelial NOS.”
BackgroundDai, S., Chen, X., Yongsheng, Y., Zang, G., & Tang, Z. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9487 · Cited by 7
“However, patients with CHB have impaired and dysfunctional HBV‑specific T cell responses (27-29).”
Chiale, C., Moshkani, S., Rose, J. K., & Robek, M. D. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.05.014 · Cited by 6
Characteristics of Circulatory γδ T cells in Patients with Symptomatic Chronic Hepatitis B Infection
Gogoi, D., Borkakoty, B., Biswas, D., Yadav, K. K., & Patel, V. V. (2021) · Viral Immunology · doi:10.1089/vim.2020.0314 · Cited by 6
“However, cellular immunity mediated by CD4 + T cells, CD8 + T cells, and natural killer cells along with inflammatory cytokines, while clearing the virus, contribute to liver damage (11,28,29).”
Old and rising stars in the lymphoid liver
Selmi, C. F., Podda, M., & Gershwin, M. E. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0175-2 · Cited by 6
“virus also appear promising for novel therapeutic developments [9–11].”
BackgroundTu, T., Wettengel, J. M., Xia, Y., Testoni, B., Littlejohn, M., Bert, N. L., Ebert, G., Verrier, E. R., Tavis, J. E., & Cohen, C. A. (2024) · Virology · doi:10.1016/j.virol.2024.110089 · Cited by 5
Xie, H., Deng, H., Yang, X., Gao, X., Yang, S., Chen, W., Wang, Y., Yang, N., Yong, L., & Hou, X. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.05.008 · Cited by 5
Gu, Y., Bi, Y., Huang, Z., Liao, C., Li, X., Hu, H., Xie, H., & Huang, Y. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2024.0178 · Cited by 5
“T-cell immunity is weaker in patients with CHB—who exhibit persistently high levels of viral replication—than in those with acute HBV infection [13, 14].”
Carotenuto, P., Artsen, A., Osterhaus, A. D. M. E., & Pontesilli, O. (2011) · Viral Immunology · doi:10.1089/vim.2010.0067 · Cited by 7
Shared immunotherapeutic approaches in HIV and hepatitis B virus: combine and conquer
Maini, M. K., & Peppa, D. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000621 · Cited by 5
Self-citationGu, Y., Li, X., Gu, L., Lian, Y., Wang, K., Chen, Y., Lai, J., Mei, Y., Liu, J., Huang, Z., et al. (2020) · Aging · doi:10.18632/aging.202274 · Cited by 5
T cell fitness in the liver: How can T cells keep it up?
Bertoletti, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.035 · Cited by 5
Self-citationRelationship Between Chronic Hepatitis B Virus Infection and Nature Killer Cells
Zhang, J., Chen, Q., & Feng, H. (2019) · Viral Immunology · doi:10.1089/vim.2018.0131 · Cited by 4
“The only effective method to block the progression of the disease is antiviral therapy, interferon-a (IFN-a ) is one of approved antiviral therapies, it acts by activating nature killer (NK) cells and NK T cells and enhancing the innate immune response to achieve viral clearance (1,2,4).”
Immune Mechanisms of Viral Clearance and Disease Pathogenesis During Viral Hepatitis
Ferrari, C. I., Barili, V., Varchetta, S., & Mondelli, M. U. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch63 · Cited by 5
Zhuo, M., Song, L., Tang, Y., Dai, S., Chen, X., Yu, Y., Zang, G., & Tang, Z. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3834 · Cited by 4
“Defects in cytokine secretion of antigen‑specific CD8 + T cells have been previously associated with chronic HBV infection (31).”
Overcoming T-cell exhaustion in glioblastoma: A narrative review
Wang, X., Wang, X., & Li, J. (2022) · Glioma · doi:10.4103/glioma.glioma_16_22 · Cited by 3
Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy
Sneller, L., Mathur, K., Kottilil, S., & Mathur, P. (2025) · Viruses · doi:10.3390/v17091255 · Cited by 4
“Chronic antigen presentation invoked by HBV induces T-cell exhaustion and immunosuppression [86].”
Metadata
- Authors
- Das, A., Hoare, M., Davies, N., Lopes, A. R., Dunn, C., Kennedy, P. T. F., Alexander, G., Finney, H., Lawson, A., Plunkett, F. J., Bertoletti, A., Akbar, A. N., & Maini, M. K.
- Affiliations
- 1Division of Infection and Immunity
- Addenbrooke's Hospital (GB)
- 2Institute of Hepatology
- Cell Biotech (South Korea) (KR)
- Agency for Science, Technology and Research (SG)
- University College London (GB)
- ORCID
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2008-08-11
- Volume
- 205
- Issue
- 9
- Pages
- 2111-2124
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC2526205
- OpenAlex
- W2020211914
- Cited by
- 256
- References
- 60
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 9 · 2023: 12 · 2022: 9 · 2021: 16 · 2020: 14 · 2019: 16 · 2018: 13 · 2017: 16 · 2016: 11 · 2015: 15 · 2014: 20 · 2013: 19 · 2012: 25
- FWCI
- 13.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University College London
- Medical Research Council
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- chronic hepatitis B, CD8+ T cells, T cell dysfunction, T cell receptor signaling, CD3zeta, arginine deprivation, IL-2 production, T cell proliferation, interferon-gamma, TNF-α, liver inflammation, intrahepatic T cells
- MeSH terms
- Adult, Aged, Female, Hepatitis B virus, Humans, Interferon-gamma, Interleukin-2, Male, Middle Aged, Models, Biological, Tumor Necrosis Factor-alpha, HLA-A2 Antigen, CD8-Positive T-Lymphocytes, Viral Load, Hepatitis B, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.